Ischemic postconditioning may increase serum fetuin-A level in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous intervention

Clinical Laboratory

Volumn 59, Issue 1-2, 2013, Pages 59-64

  Liu, Sheng Hui ^a   Huo, Yu E ^a   Yin, Bo Ying ^a   Li, Xiao Hong ^a   Wang, Yan Fei ^a  

^a HEBEI UNIVERSITY   (China)

Author keywords

Fetuin A; Hs CRP; Ischemic postconditioning; Myocardial infarction

Indexed keywords

C REACTIVE PROTEIN; CREATINE KINASE MB; FETUIN A;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEART MUSCLE REPERFUSION; HUMAN; ISCHEMIC POSTCONDITIONING; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME;

AGED; ALPHA-2-HS-GLYCOPROTEIN; CASE-CONTROL STUDIES; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; ISCHEMIC POSTCONDITIONING; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION;

EID: 84874626831     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2012.120222     Document Type: Article

References (35)

1. Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003;285:H579-88. (Pubitemid 36885888)
2. Galagudza M, Kurapeev D, Minasian S, Valen G, Vaage J. Ischemic postconditioning: brief ischemia during reperfusion converts persistent ventricular fibrillation into regular rhythm. Eur J Cardiothorac Surg 2004;25:1006-10. (Pubitemid 38622342)
3. Staat P, Rioufol G, Piot C, et al. Postconditioning the human heart. Circulation 2005;112:2143-8. (Pubitemid 41475808)
4. Lim P, Collet JP, Moutereau S, et al. Fetuin-A is an independent predictor of death after ST-elevation myocardial infarction. Clin Chem 2007;53:1835-40. (Pubitemid 47509678)
5. Basar N, Sen N, Kanat S, et al. Lower Fetuin-A predicts angiographic impaired reperfusion and mortality in ST-elevation myocardial infarction. J Invest Med 2011;59:816-22.
6. Yang X C, Liu Y, Wang L F, et al. Reduction in myocardial infarct size by postconditioning in patients after percutaneous coronary intervention. J Invasive Cardiol 2007;19:424-30. (Pubitemid 47509466)
7. Ma X, Zhang X, Li C, Luo M. Effect of postconditioning on coronary blood flow velocity and endothelial function and LV recovery after myocardial infarction. J Interv Cardiol 2006;19: 367-75. (Pubitemid 44511065)
8. Kin H, Zhao Z Q, Sun H Y, et al. Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion. Cardiovasc Res 2004;62:74-85. (Pubitemid 38326813)
9. Yang XM, Proctor JB, Cui L, Krieg T, Downey JM, Cohen MV. Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J Am Coll Cardiol2004;44:1103-10. (Pubitemid 39165147)
10. Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM. Postconditioning: a form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway Circ Res 2004;95:230-2. (Pubitemid 39056282)
11. Kin H, Zatta A J, Lofye M T, et al. Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine. Cardiovasc Res 2005;67:124-33. (Pubitemid 40798299)
12. Obal D, Dettwiler S, Favoccia C, Scharbatke H, Preckel B, Schlack W. The influence of mitochondrial KATP-channels in the cardioprotection of preconditioning and postconditioning by sevoflurane in the rat in vivo. Anesth Analg 2005;101:1252-60. (Pubitemid 41531854)
13. Argaud L, Gateau-Roesch O, Raisky O, Loufouat J, Robert D, Ovize M. Postconditioning inhibits mitochondrial permeability transition. Circulation 2005;111:194-7. (Pubitemid 40139731)
14. Darling CE, Jiang R, Maynard M, Whittaker P, Vinten-Johansen J, Przyklenk K. Postconditioning via stuttering reperfusion limits myocardial infarct size in rabbit hearts: role of ERK1/2. Am J Physiol Heart Circ Physiol 2005;289:H1618-26. (Pubitemid 41369005)
15. McCully JD, Wakiyama H, Hsieh YJ, Jones M, Levitsky S. Differential contribution of necrosis and apoptosis in myocardial ischemia-reperfusion injury, Am J Physiol Heart Circ Physiol, 286 (2004) H1923-26.
16. Lauzier B, Delemasure S, Debin R, etc. Beneficial effects of myocardial postconditioning are associated with reduced oxidative stress in a senescent mouse model. Transplantation 2008;85:1802-8.
17. Mykytenko J, Reeves JG, King H, etc. Persistent beneficial effect of postconditioning against infarct size: role of mitochondrial K(ATP) channels during reperfusion. Basic Res Cardiol 2008;103:472-84.
18. Cohen MV, Yang XM, Downey JM. Acidosis, oxygen, and interference with mitochondrial permeability transition pore formation in the early minutes of reperfusion are critical to postconditioning's success. Basic Res Cardiol 2008;103:464-71.
19. Fang J, Wu L, Chen L. Postconditioning attenuates cardiocyte ultrastructure injury and apoptosis by blocking mitochondrial permeability transition in rats. Acta Cardiol, 63 (2008) 377-87. (Pubitemid 351929846)
20. Jang Y, Xi J, Wang H, Mueller R A, Norfleet EA, Xu Z. Postconditioning prevents reperfusion injury by activating delta-opioid receptors. Anesthesiology 2008;108:243-50. (Pubitemid 351156734)
21. Libby P. Changing concepts of atherogenesis. J Intern Med 2000;247:349-58. (Pubitemid 30180037)
22. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res 2004;61:481-97. (Pubitemid 38210154)
23. Kennedy TP, Vinten-Johansen J. A review of the clinical use of anti-inflammatory therapies for reperfusion injury in myocardial infarction and stroke: where do we go from here? Curr Opin Investig Drugs 2006;7:229-41.7.
24. Shak PK. Circulating markers of inflammation for vascular risk prediction: are they ready for prime time? Circulation 2000;101:1758-9.
25. Mueller C, Buettner HJ, Hodgson JM, et al. Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation 2002;105:1412-5. (Pubitemid 34263269)
26. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-65. (Pubitemid 35315836)
27. Rider PM. Novel risk factors and makers for coronary disease. Adv Intern Med 2000;45:391-418.
28. Szmitko PE, Wang CH, Weisel RD, et al. New makers of inflammation and endothelial cell activation: part I. Circulation 2003;108:1917-23. (Pubitemid 37296533)
29. Nijmeijer R, Lagrand WK, Visser CA. CRP, a major culprit in complement-mediated tissue damage in acute myocardial infarction? Int Immunopharmacol 2001;1:403-14. (Pubitemid 32197539)
30. Xue F, Yang X, Zhang B, et al. Postconditioning the Human Heart in Percutaneous Coronary Intervention. Clin Cardiol 2010;33(7):439-44.
31. Kishore BK, Gejyo F, Arakawa M. Alpha 2HS-glycoprotein in the serum and urine of patients with renal diseases. Postgrad Med J 1983;59:304-7. (Pubitemid 13079856)
32. Wang H, Zhang M, Bianchi M, Sherry B, Sama A, Tracey KJ. Fetuin (alpha2-HS-glycoprotein) opsonizes cationic macrophage deactivating molecules. Proc Natl Acad Sci USA 1998;95:14429-34.
33. Demetriou M, Binkert C, Sukhu B, Tenenbaum HC, Dennis JW. Fetuin/alpha2-HS glycoprotein is a transforming growth factor beta type II receptor mimic and cytokine antagonist. J Biol Chem 1996;271:12755-61. (Pubitemid 26175845)
34. Reynolds JL, Skepper JN, McNair R, et al. Multifunctional roles for serum protein fetuin-A in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol 2005;16:2920-30. (Pubitemid 44743490)
35. Weikert C, Stefan N, Schulze MB, et al. Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke. Circulation 2008;118:2555-62.